AzTrials
AzTrials

Inflammatory Bowel DiseaseNCT05973500

Effect of Mediterranean Diet in Inflammatory Bowel Disease

A study testing Mediterranean Diet in people with Inflammatory Bowel Disease, run by University of California, San Diego at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The effects of diet on inflammatory bowel disease is an under-studied area of research. The investigators are interested in further investigating the role that diet contributes to inflammatory bowel disease severity. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Inflammatory Bowel Disease
What is being tested?
Mediterranean Diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteUnited States
Study dates
1 Sep 2023to 1 Aug 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years old or older
  • Meet classification criteria for inflammatory bowel disease including those with mild to moderate Crohn's Disease as defined by a Crohn's disease activity index between 150-450, with fecal calprotectin>250, within 1 month of enrollment.

Who cannot join

  • Unable to provide informed consent
  • History of or current drug abuse
  • Pregnancy
  • Start or change in dose of standard-of-care treatment within 12 weeks of the screening
  • Known allergy to any component of the proposed diet
  • Subjects with significant other medical or psychiatric comorbidities and /or medication use which in
Show all 10Show fewer
  • physician's clinical judgment might difficult the interpretation of the results
  • Patients that are not on a stable dose of medications, for instance, steroids, in between samples collection
  • Patients on antibiotics
  • Patients with C difficile infection within 4 weeks of enrollment

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Monica Guma, M.D., PhD contact

8588226523

mguma@health.ucsd.edu

Mehrnaz Aghili, M.D. contact

8582464721

maghili@health.ucsd.edu

United States1 site, 1 recruiting
  • University of California, San Diego

    San Diego, California, 92161

    Monica Guma, M.D, PHD, mguma@health.ucsd.edu

    Brigid Boland, M.D

    Recruiting

Other trials in United States

About this study

Official title: Implementing Metabolomics Informed Diet on Inflammatory Bowel Disease Patients

The effects of diet on inflammatory bowel disease is an under-studied area of research. The investigators are interested in further investigating the role that diet contributes to inflammatory bowel disease severity. The investigators will collect blood and stool samples from patients with inflammatory bowel disease (IBD) before and after diet changes. The stool samples will be analyzed using metabolomics and microbiome analysis to determine changes after the new diet has been implemented. The investigators will then compare changes in the patient's overall disease state by measuring markers of inflammation including C-reactive protein (CRP) and fecal calprotectin to determine how this diet affects the disease state.

Being tested
Mediterranean Diet
Medical subject headings
Inflammatory Bowel Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mediterranean DietDietary supplement

    Mediterranean Diet for 42 Days

Study groups in NCT05973500
Study groupRoleWhat they receive
Mediterranean DietExperimentalMediterranean Diet for 42 Days
Receives: Dietary Supplement: Mediterranean Diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. short Crohn's Disease Activity Index (sCDAI)

    Mild to moderate Crohn's Disease is defined by a short Crohn's Disease activity index (sCDAI) between 150-450, while those in remission from Crohn's Disease have an sCDAI score below 150. An sCDAI score exceeding 450 is used as a marker of severe Crohn's Disease.

    Measured: 42 Days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2023
  2. Study start1 Sep 2023
  3. Primary completion1 Aug 2028 (estimated)
  4. Study completion1 Aug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05973500
Sponsor's protocol ID
800805
Status last verified
Nov 2026
First submitted
25 Jul 2023
Last updated
6 Nov 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Mediterranean Diet in people with Inflammatory Bowel Disease, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Monica Guma, M.D., PhD (8588226523, mguma@health.ucsd.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

short Crohn's Disease Activity Index (sCDAI) (time frame: 42 Days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in